Heart failure drug Entresto sales grew 34% at constant currency, driven by strong demand and greater market share in the U.S. and Europe for heart failure treatment. It also saw increased use in ...

Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer drugs delivered robust growth, though missed on its ...

(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it’s not an opioid. The drug is suzetrigine under the brand name ...

MSN Laboratories Pvt. Ltd. infringed a recently revived Novartis AG patent by importing and preparing to distribute large quantities of its copies of the blockbuster heart-failure drug Entresto before ...

Common medications might hold the key to preventing dementia, according to a vast study. Repurposing drugs like antibiotics could offer a swift and economical approach to managing dementia, suggesting ...

As part of a flurry of executive actions on the first day of his second White House term, President Donald Trump on Monday rescinded an order signed by his predecessor that aimed to develop programs ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto ...

Entresto’s importance to Novartis is illustrated in the company’s most recent quarterly report, which revealed that the drug generated $5.6 billion in the first three quarters of 2024 ...

WASHINGTON, Jan 16 - Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals ...

the validity of the U.S. patent covering Novartis’s blockbuster drug Entresto was upheld, reversing an earlier decision by the U.S. District Court in Delaware that the patent was invalid.

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto. Novartis on Thursday secured a last-minute win against MSN ...